General Discussion

So I searched and found this article in the Journal Nature Flawed ivermectin preprint highlights challenges of COVID drug studies. The gist of it is that a preprint study was widely read and cited, but it was flawed:

...dozens of patient records that seemed to be duplicates, inconsistencies between the raw data and the information in the paper, patients whose records indicate they died before the study’s start date, and numbers that seemed to be too consistent to have occurred by chance.

We had a similar thing with hydroxychloroquine and that didn't pan out either: New England Journal of Medicine, A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.

There are other studies that have similar defects. The Journal article goes on to say that yes, a study of this drug needs to be done, a study in Brazil is ongoing and might be useful. Recruiting subjects for the studies have proven difficult since so many in Latin America already take this particular drug. However, developed countries already have effective treatments and vaccines, so they have little interest in this drug.